Transcriptional regulation of the human TNFSF11 gene in T cells via a cell type-selective set of distal enhancers

Journal of Cellular Biochemistry

Volumn 116, Issue 2, 2015, Pages 320-330

  Bishop, Kathleen A ^a,b   Wang, Xiaohua ^a,c   Coy, Heidi M ^a   Meyer, Mark B ^a   Gumperz, Jenny E ^a   Pike, J Wesley ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Maine Medical Center Research Institute   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

C FOS; Chip chip analysis; Distal enhancers; Epigenetic marks; T cell rankl

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; DNA; HISTONE H3; HISTONE H4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ARTICLE; BONE DENSITY; CELL TYPE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENHANCER REGION; ENZYME INHIBITION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; JURKAT CELL LINE; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; TRANSIENT TRANSFECTION; CELL CULTURE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; LYMPHOCYTE ACTIVATION; METABOLISM; REGULATORY SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BONE DENSITY; CELLS, CULTURED; ENHANCER ELEMENTS, GENETIC; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MAP KINASE KINASE 1; MAP KINASE KINASE 2; POLYMORPHISM, SINGLE NUCLEOTIDE; RANK LIGAND; REGULATORY SEQUENCES, NUCLEIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 84916608044     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24974     Document Type: Article

References (53)

1. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L. 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179.
2. Bishop KA, Coy HM, Nerenz RD, Meyer MB, Pike JW. 2011. Mouse Rankl expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control region. J Biol Chem 286:20880-20891.
3. Bishop KA, Meyer MB, Pike JW. 2009. A novel distal enhancer mediates cytokine induction of mouse RANKl gene expression. Mol Endocrinol 23:2095-2110.
4. Blanchette M, Kent WJ, Riemer C, Elnitski L, Smit AF, Roskin KM, Baertsch R, Rosenbloom K, Clawson H, Green ED, Haussler D, Miller W. 2004. Aligning multiple genomic sequences with the threaded blockset aligner. Genome Res 14:708-715.
5. Burkiewicz JS, Scarpace SL, Bruce SP. 2009. Denosumab in osteoporosis and oncology. Ann Pharmacother 43:1445-1455.
6. Choi JK, Howe LJ. 2009. Histone acetylation: Truth of consequences? Biochem Cell Biol 87:139-150.
7. Crispin JC, Tsokos GC. 2009. Transcriptional regulation of IL-2 in health and autoimmunity. Autoimmun Rev 8:190-195.
8. Dai SM, Nishioka K, Yudoh K. 2004. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: Comparison with IL1 beta and tumour necrosis factor alpha. Ann Rheum Dis 63:1379-1386.
9. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, Epstein CB, Zhang X, Wang L, Issner R, Coyne M, Ku M, Durham T, Kellis M, Bernstein BE. 2011. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473:43-49.
10. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM. 2000. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103:41-50.
11. Fionda C, Nappi F, Piccoli M, Frati L, Santoni A, Cippitelli M. 2007. 15-deoxy-Delta12,14-prostaglandin J2 negatively regulates rankl gene expression in activated T lymphocytes: Role of NF-kappaB and early growth response transcription factors. J Immunol 178:4039-4050.
12. Fu Q, Manolagas SC, O'Brien CA. 2006. Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol 26:6453-6468.
13. Galli C, Zella LA, Fretz JA, Fu Q, Pike JW, Weinstein RS, Manolagas SC, O'Brien CA. 2008. Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass. Endocrinology 149:146-153.
14. Gendron S, Couture J, Aoudjit F. 2005. Collagen type I signaling reduces the expression and the function of human receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes. Eur J Immunol 35:3673-3682.
15. Guttormsen J, Koster MI, Stevens JR, Roop DR, Williams T, Winger QA. 2008. Disruption of epidermal specific gene expression and delayed skin development in AP-2 gamma mutant mice. Dev Biol 317:187-195.
16. Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, Nishihara T, Takahashi N, Suda T. 1999. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 163:434-442.
17. Josien R, Wong BR, Li HL, Steinman RM, Choi Y. 1999. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 162:2562-2568.
18. Kanamaru F, Iwai H, Ikeda T, Nakajima A, Ishikawa I, Azuma M. 2004. Expression of membrane-bound and soluble receptor activator of NF-kappaB ligand (RANKL) in human T cells. Immunol Lett 94:239-246.
19. Kim HP, Imbert J, Leonard WJ. 2006a. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev 17:349-366.
20. 3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts. J Bone Miner Res 20:305-317.
21. Kim S, Yamazaki M, Shevde NK, Pike JW. 2007. Transcriptional control of receptor activator of nuclear factor-kappaB ligand by the protein kinase A activator forskolin and the transmembrane glycoprotein 130-activating cytokine, oncostatin M, is exerted through multiple distal enhancers. Mol Endocrinol 21:197-214.
22. 3 is mediated through multiple long-range enhancers. Mol Cell Biol 26:6469-6486.
23. Kurdistani SK, Tavazoie S, Grunstein M. 2004. Mapping global histone acetylation patterns to gene expression. Cell 117:721-733.
24. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
25. Leibbrandt A, Penninger JM. 2008. RANK/RANKL: Regulators of immune responses and bone physiology. Ann N Y Acad Sci 1143:123-150.
26. Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S, Schwarz T, Penninger JM, Beissert S. 2006. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 12:1372-1379.
27. 3 during osteoblast-lineage cell differentiation. J Biol Chem 289:19539-19554.
28. Meyer MB, Benkusky NA, Pike JW. 2014b. The RUNX2 cistrome in osteoblasts: Characterization, down-regulation following differentiation, and relationship to gene expression. J Biol Chem 289:16016-16031.
29. 3. J Biol Chem 285:15599-15610.
30. Nakashima T, Wada T, Penninger JM. 2003. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 15:280-287.
31. 3. Mol Endocrinol 22:1044-1056.
32. 3 in bone cells: Exploiting new approaches and defining new mechanisms. Bonekey Rep 3:482.
33. Pike JW, Meyer MB. 2014. Fundamentals of vitamin D hormone-regulated gene expression. J Steroid Biochem Mol Biol 144:5-11.
34. Rinotas V, Niti A, Dacquin R, Bonnet N, Stolina M, Han CY, Kostenuik P, Jurdic P, Ferrari S, Douni E. 2014. Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice. J Bone Miner Res 29:1158-1169.
35. Rivadeneira F, Styrkarsdottir U, Estrada K, Halldorsson BV, Hsu YH, Richards JB, Zillikens MC, Kavvoura FK, Amin N, Aulchenko YS, Cupples LA, Deloukas P, Demissie S, Grundberg E, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra B, Pastinen T, Pols HA, Sigurdsson G, Soranzo N, Thorleifsson G, Thorsteinsdottir U, Williams FM, Wilson SG, Zhou Y, Ralston SH, van Duijn CM, Spector T, Kiel DP, Stefansson K, Ioannidis JP, Uitterlinden AG. 2009. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 41:1199-1206.
36. Roh TY, Cuddapah S, Zhao K. 2005. Active chromatin domains are defined by acetylation islands revealed by genome-wide mapping. Genes Dev 19:542-552.
37. Roh TY, Wei G, Farrell CM, Zhao K. 2007. Genome-wide prediction of conserved and nonconserved enhancers by histone acetylation patterns. Genome Res 17:74-81.
38. Roshandel D, Holliday K, Pye SR, Boonen S, Borghs H, Vanderschueren D, Huhtaniemi IT, Adams JE, Ward KA, Bartfai G, Casanueva F, Finn JD, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Silman AJ, Wu FC, Thomson W, O'Neill TW. 2010. Genetic variation in the RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in men. J Bone Miner Res 25:1830-1838.
39. Schubeler D, MacAlpine DM, Scalzo D, Wirbelauer C, Kooperberg C, van Leeuwen F, Gottschling DE, O'Neill LP, Turner BM, Delrow J, Bell SP, Groudine M. 2004. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev 18:1263-1271.
40. Silverman SL. 2009. New therapies for osteoporosis: Zoledronic acid, bazedoxifene, and denosumab. Curr Osteoporos Rep 7:91-95.
41. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Center JR, Nguyen TV, Bagger Y, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K. 2008. Multiple genetic loci for bone mineral density and fractures. N Engl J Med 358:2355-2365.
42. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Snorradottir S, Center JR, Nguyen TV, Alexandersen P, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K. 2009. New sequence variants associated with bone mineral density. Nat Genet 41:15-17.
43. Suda T, Takahashi N, Martin TJ. 1992. Modulation of osteoclast differentiation. Endocr Rev 13:66-80.
44. Teitelbaum SL. 2000. Bone resorption by osteoclasts. Science 289:1504-1508.
45. Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, Kivioja T, Bjorklund M, Wei G, Yan J, Niittymaki I, Mecklin JP, Jarvinen H, Ristimaki A, Di-Bernardo M, East P, Carvajal-Carmona L, Houlston RS, Tomlinson I, Palin K, Ukkonen E, Karhu A, Taipale J, Aaltonen LA. 2009. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet 41:885-890.
46. Wagner EF, Eferl R. 2005. Fos/AP-1 proteins in bone and the immune system. Immunol Rev 208:126-140.
47. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, Cui K, Roh TY, Peng W, Zhang MQ, Zhao K. 2008. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 40:897-903.
48. Wang R, Zhang L, Zhang X, Moreno J, Celluzzi C, Tondravi M, Shi Y. 2002. Regulation of activation-induced receptor activator of NF-kappaB ligand (RANKL) expression in T cells. Eur J Immunol 32:1090-1098.
49. Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM, Choi Y. 1997a. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 186:2075-2080.
50. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, 3rd, Frankel WN, Lee SY, Choi Y. 1997b. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272:25190-25194.
51. Wright JB, Brown SJ, Cole MD. 2010. Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. Mol Cell Biol 30:1411-1420.
52. Yamamoto H, Shevde NK, Warrier A, Plum LA, DeLuca HF, Pike JW. 2003. 2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. J Biol Chem 278:31756-31765.
53. Zella LA, Meyer MB, Nerenz RD, Lee SM, Martowicz ML, Pike JW. 2010. Multifunctional enhancers regulate mouse and human vitamin D receptor gene transcription. Mol Endocrinol 24:128-147.